02 December 2024
02 December 2024
The BEST4 trial will consider the capsule sponge device for a future screening programme for Barrett’s oesophagus.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Per GlobalData estimates, the heart failure market size across the 7MM was $13.5 billion in 2022, and is anticipated to grow at a strong CAGR of more than 9% from 2022 to 2032, primarily fuelled by anticipated label expansion for Bayer’s Kerendia (finerenone), launch of several oral and injectable agents and an increase in the global prevalence of chronic HF. The report also provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Give your business an edge with our leading industry insights.
